Sarclisa Triple Combo Approved in Europe for Advanced Myeloma Patients
The European Commission (EC) has approved Sanofi‘s Sarclisa (isatuximab), in a triple combination with Pomalyst (pomalidomide) and dexamethasone, to treat adults…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
CHMP Favors Darzalex Faspro in Treating Patients in EU
Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro, has been recommended for approval…
FDA Asks for More Data on Ide-cel as Potential Multiple Myeloma Therapy
The U.S. Food and Drug Administration (FDA) asked for more information from Bristol Myers Squibb and Bluebird Bio as it considers a…
Cell Protein Analysis May Predict Multiple Myeloma Response to Treatment
A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively treat people with …
FDA Approves Darzalex Faspro as Injection Therapy for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved Janssen‘s new formulation of daratumumab — a subcutaneous or under-the-skin injection treatment called Darzalex Faspro…
Actemra May Treat Severe COVID-19 Infections in Myeloma Patients, Case Report Suggests
Actemra (tocilizumab), a medicine approved for certain types of arthritis, may be effective in treating severe infections with the new coronavirus in…
